Literature DB >> 28880786

Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.

Philipp Boehm-Sturm1, Akvile Haeckel1, Ralf Hauptmann1, Susanne Mueller1, Christiane K Kuhl1, Eyk A Schellenberger1.   

Abstract

Purpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with those of a commercial gadolinium-based contrast agent for their applicability in dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging. Materials and Methods The animal experiments were approved by the local ethics committee. Two previously described iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) were synthesized with stability constants several orders of magnitude higher than those of gadolinium-based contrast agents. The T1 contrast effects of the two chelates were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7 T. For in vivo studies, a human breast cancer cell line (MDA-231) was implanted in five mice per group. The dynamic contrast effects of the chelates were compared by performing DCE MR imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same tumors with gadopentetate dimeglumine on day 2. Quantitative DCE maps were generated with software and were compared by means of a one-tailed Pearson correlation test. Results Relaxivities in serum (0.94 T at room temperature) of Fe-tCDTA (r1 = 2.2 mmol-1 · sec-1, r2 = 2.5 mmol-1 · sec-1) and Fe-DTPA (r1 = 0.9 mmol-1 · sec-1, r2 = 0.9 mmol-1 · sec-1) were approximately twofold and fivefold lower, respectively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol-1 · sec-1, r2 = 4.8 mmol-1 · sec-1). Used at moderately higher concentrations, however, iron chelates generated similar contrast effects at T1-weighted MR imaging in vitro in serum, in vivo in blood, and for DCE MR imaging of breast cancer xenografts. The volume transfer constant values for Fe-DTPA and Fe-tCDTA in the same tumors correlated well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTPA Pearson R, 0.97; P = .003). Conclusion Iron-based contrast agents are promising as alternatives for contrast enhancement at T1-weighted MR imaging and have the potential to contribute to the safety of MR imaging. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28880786     DOI: 10.1148/radiol.2017170116

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

Review 1.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

2.  A Class of FeIII Macrocyclic Complexes with Alcohol Donor Groups as Effective T1 MRI Contrast Agents.

Authors:  Eric M Snyder; Didar Asik; Samira M Abozeid; Ariel Burgio; Gage Bateman; Steven G Turowski; Joseph A Spernyak; Janet R Morrow
Journal:  Angew Chem Int Ed Engl       Date:  2019-12-20       Impact factor: 15.336

3.  Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex.

Authors:  Huan Wang; Veronica Clavijo Jordan; Ian A Ramsay; Mozhdeh Sojoodi; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  J Am Chem Soc       Date:  2019-03-28       Impact factor: 15.419

4.  Development of a Novel MR Colonography via Iron-Based Solid Lipid Nanoparticles.

Authors:  Huiyang Wang; Siqi Wang; Xisong Zhu; Wenxiu Ding; Tianlun Shen; Hongjie Fan; Yanhua Zhang; Lijun Peng; Hong Yuan; Xiangrui Liu; Jun Ling; Jihong Sun
Journal:  Int J Nanomedicine       Date:  2022-02-22

5.  Metal-Organic Polyhedron with Four Fe(III) Centers Producing Enhanced T1 Magnetic Resonance Imaging Contrast in Tumors.

Authors:  Gregory E Sokolow; Matthew R Crawley; Daniel R Morphet; Didar Asik; Joseph A Spernyak; A J Robert McGray; Timothy R Cook; Janet R Morrow
Journal:  Inorg Chem       Date:  2022-01-24       Impact factor: 5.436

6.  Liposomal Fe(III) Macrocyclic Complexes with Hydroxypropyl Pendants as MRI Probes.

Authors:  Samira M Abozeid; Md Saiful I Chowdhury; Didar Asik; Joseph A Spernyak; Janet R Morrow
Journal:  ACS Appl Bio Mater       Date:  2021-10-15

Review 7.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

8.  MRI and fluorescence studies of Saccharomyces cerevisiae loaded with a bimodal Fe(III) T1 contrast agent.

Authors:  Akanksha Patel; Didar Asik; Joseph A Spernyak; Paul J Cullen; Janet R Morrow
Journal:  J Inorg Biochem       Date:  2019-09-06       Impact factor: 4.155

9.  Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.

Authors:  Junfeng Wang; Huan Wang; Ian A Ramsay; Derek J Erstad; Bryan C Fuchs; Kenneth K Tanabe; Peter Caravan; Eric M Gale
Journal:  J Med Chem       Date:  2018-09-25       Impact factor: 7.446

10.  Improving workflow in prostate MRI: AI-based decision-making on biparametric or multiparametric MRI.

Authors:  Andreas M Hötker; Raffaele Da Mutten; Anja Tiessen; Ender Konukoglu; Olivio F Donati
Journal:  Insights Imaging       Date:  2021-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.